Transl Clin Pharmacol.  2019 Sep;27(3):87-88. 10.12793/tcp.2019.27.3.87.

Artificial intelligence in drug development: clinical pharmacologist perspective

• Jang IJ

• KMID: 2458946
• DOI: http://doi.org/10.12793/tcp.2019.27.3.87

Abstract

No abstract available.

MeSH Terms

Artificial Intelligence*

Figure

• 

  Figure 1 Utilisation of artificial intelligence (AI) in the drug development process. The outcomes and strategies of the various components of the drug development process are described. The applications of AI at each stage of drug development are also shown.[3] (from Drug Discovery Today. Volume 24, Number 3, March 2019)

Reference

1. Esteva A, Robicquet A, Ramsundar B, Kuleshov V, DePristo M, Chou K, et al. A guide to deep learning in healthcare. Nat Med. 2019; 25:24–29. DOI: 10.1038/s41591-018-0316-z.

2. Bakkar N, Kovalik T, Lorenzini I, Spangler S, Lacoste A, Sponaugle K, et al. Artificial intelligence in neurodegenerative disease research: use of IBM Watson to identify additional RNA-binding proteins altered in amyotrophic lateral sclerosis. Acta Neuropathol. 2018; 135:227–247. DOI: 10.1007/s00401-017-1785-8.

3. Mak KK, Pichika MR. Artificial intelligence in drug development: present status and future prospects. Drug Discov Today. 2019; 24:773–780. DOI: 10.1016/j.drudis.2018.11.014.

4. Harrer S, Shah P, Antony B, Hu J. Artificial Intelligence for Clinical Trial Design. Trends Pharmacol Sci. 2019; 40:577–591. DOI: 10.1016/j.tips.2019.05.005.